Sanofi ends Phase 3 riliprubart trial after weak interim results

Biopharmaceutical company Sanofi will stop a Phase ​3 trial of its drug ‌riliprubart for a rare neurological condition after an interim ​analysis of the ​study found it unlikely to ⁠provide sufficient efficacy.

Reuters • Jun 10, 2026

Press Release: Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy

Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy Paris, June 10, 2026 .  Sanofi today announced that the riliprubart MOBILIZE phase 3 study (clinical study identifier: NCT06290128) in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) refractory to standard-of-care treatment will be stopped.

GlobeNewsWire • Jun 10, 2026

Sanofi Ends Late-Stage Study on Neurology Drug Over Weak Results

SNY halts its phase III MOBILIZE study after an interim review finds riliprubart unlikely to deliver sufficient efficacy in refractory CIDP patients.

Zacks Investment Research • Jun 10, 2026

Sanofi to Stop Late-Stage Study of Immune-Disorder Drug

The termination is an early setback to new chief executive Belen Garijo, who took the helm last month.

WSJ • Jun 10, 2026

Sanofi, An Argenx Rival, Bites The Dust — But A Third Biotech Took The Biggest Hit

Sanofi scrapped a final-phase study Wednesday of an experimental CIDP treatment. The stock tumbled in response.

Investors Business Daily • Jun 10, 2026

Sanofi Wins EU Nod for Subcutaneous Sarclisa in Multiple Myeloma

SNY wins EU approval for a subcutaneous Sarclisa option in multiple myeloma, offering faster administration and flexible delivery methods.

Zacks Investment Research • Jun 8, 2026

Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi

NEW YORK & PARIS--(BUSINESS WIRE)--Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin's AI Scientist. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The co.

Business Wire • Jun 5, 2026

Press Release: Sanofi launches 2026 global employee stock purchase plan

Sanofi launches 2026 global employee stock purchase plan Paris, June 4, 2026. Sanofi's global employee shareholder plan, Action 2026, opens on June 9, 2026, to around 75,000 employees in 52 countries.

GlobeNewsWire • Jun 4, 2026

Sanofi Stock Falls 6% in 3 Months: Should You Buy, Sell or Hold?

Sanofi shares slip despite strong growth. However, Dupixent, new launches, pipeline progress and a low valuation support staying invested.

Zacks Investment Research • Jun 4, 2026

FDA Grants Priority Review to SNY's Filing for Gaucher Disease Drug

Sanofi secures FDA priority review for venglustat in GD3, setting up a November decision on a potential first U.S. therapy for neurological symptoms.

Zacks Investment Research • May 29, 2026